Key Takeaways GSK wins Japan orphan drug status for risvutatug rezetecan in small-cell lung cancer.GSK's phase I ARTEMIS-001 showed durable responses in extensive-stage SCLC patients.The candidate also holds FDA Breakthrough and EMA PRIME status, supporting accelerated development.GSK plc (GSK) announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to risvutatug rezetecan, its investigational B7-H3-targeted antibody-drug conjugate (“ADC”), for the treatment o ...

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $1.3 million, down from $3.1 million in Q4 2024, representing a decline of approximately 58.1% [23] - For the full year 2025, total revenue was $6.4 million, compared to $29.6 million in 2024, a decrease of about 78.4% [23] - Total operating costs and expenses for Q4 2025 were $14.8 million, up from $10.3 million in Q4 2024 [23] - For the full year 2025, total operating costs and expenses were $52.3 million, significantly reduced from $180 million in 2024 [23] - The net loss for Q4 2025 was $14.6 million, or $3.61 per share, compared to a net loss of $8.7 million, or $2.15 per share in Q4 2024 [25] - The net loss for the full year 2025 was $58.2 million, or $14.40 per share, down from a net loss of $153.1 million, or $38.26 per share in 2024 [25] - As of December 31, the company reported $109.4 million in cash equivalents, investments, and accounts receivable, with a cash runway expected into 2028 [26] Business Line Data and Key Metrics Changes - The company is advancing the FG-3246 program, a potential first-in-class antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer [4][5] - The FG-3246 program is expected to address a significant unmet need in late-stage prostate cancer, with an estimated total addressable market of over $5 billion annually in the U.S. [8] - Roxadustat is being developed for anemia associated with lower-risk myelodysplastic syndromes (MDS), with a significant opportunity due to the lack of oral treatments currently available [18][22] Market Data and Key Metrics Changes - Approximately 290,000 men are diagnosed with prostate cancer each year in the U.S., with about 65,000 drug-treatable patients with metastatic disease that has become castration-resistant [7] - The incidence of grade 3 or greater neutropenia was substantially reduced with the utilization of GCSF prophylaxis in ongoing trials [12] Company Strategy and Development Direction - The company aims to rebrand from FibroGen to Kyntra Bio to better reflect its focus on oncology and rare diseases [7] - The strategy includes advancing mid and late-stage assets and simplifying the capital structure to create value for shareholders [7] - The company is focused on developing FG-3246 and its companion FG-3180 program, with expected interim analysis from the phase 2 monotherapy trial in the second half of 2026 [27] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2025 as a transformational year, emphasizing the importance of reducing fixed costs to maximize cash runway and invest in U.S. pipeline opportunities [26] - The company remains confident in its positioning to create meaningful therapeutic options for patients and significant value for shareholders [7] Other Important Information - The company has received orphan drug designation for roxadustat, which provides a minimum of 7 years of regulatory exclusivity [22] - The company is exploring opportunities to develop roxadustat internally or with a strategic partner [21] Q&A Session Summary Question: Imaging of CD46 opportunity and commercial potential - Management discussed the potential market for CD46 PET imaging agents and how they would fit into the treatment algorithm alongside existing PSMA agents [30][32] - The company anticipates that patients will need to show positive uptake of CD46 PET imaging to be prescribed FG-3246, similar to the requirements for PSMA agents [34] Question: SUV data and patient selection - Management acknowledged the provocative nature of the SUV data and its potential role in enriching patient selection for treatment [30][40] - The phase 2 trial is designed to define CD46 positivity, which may be based on SUV or other metrics [40] Question: Balance of patients in studies and recruitment - Management clarified that the phase 2 monotherapy trial will focus on patients who have progressed on only one prior ARPI, differentiating it from the IST [46] Question: Updates on roxadustat partnering efforts - Management stated that they are evaluating the opportunity to develop roxadustat internally or through collaboration but did not provide specific updates on the partnering process [49] Question: FDA feedback timeline for roxadustat - Management explained that the FDA indicated a feedback timeline of 60-90 days due to the nature of the protocol submission, which is currently being awaited [53]

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved therapies Patent protection extends into 2038 QTORIN™ rapamycin has previously been granted European Orphan Drug Designation for the treatment of microcystic lymphatic malformations, potentially providing 10 years of market exclusivity in the European Union upon approval Th ...

Core Viewpoint - Telix Pharmaceuticals has resubmitted a New Drug Application (NDA) for TLX101-Px, an investigational PET imaging agent for glioma characterization, to the U.S. FDA, addressing previous feedback and aiming for expedited review due to significant unmet medical needs [1][2][3]. Group 1: Product Information - TLX101-Px is a PET imaging agent targeting LAT1 and LAT2 membrane transport proteins, potentially serving as a companion diagnostic for TLX101-Tx, a glioblastoma therapy candidate [5]. - The agent has received Orphan Drug and Fast Track designations from the FDA, highlighting its potential to meet critical medical needs in glioma diagnosis and management [3][5]. Group 2: Clinical Context - Gliomas account for approximately 30% of all brain and CNS tumors and 80% of malignant brain tumors, with an annual diagnosis rate of six cases per 100,000 people in the U.S. [6]. - GBM, a high-grade glioma, is the most aggressive form of primary brain cancer, with around 22,000 new cases diagnosed each year in the U.S. [6]. Group 3: Company Overview - Telix Pharmaceuticals is a global biopharmaceutical company focused on developing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, and listed on both the ASX and NASDAQ [7].

Core Insights - Eledon Pharmaceuticals has received Orphan Drug designation from the FDA for tegoprubart, aimed at preventing allograft rejection in liver transplantation [1][2] - Tegoprubart has previously been designated for pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis (ALS) [1] - The company is optimistic about the potential of tegoprubart in liver transplantation, supported by preclinical evidence and plans for an investigator-sponsored trial later this year [2] Company Overview - Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3] - The lead product, tegoprubart, is an anti-CD40L antibody with high affinity for the CD40 Ligand, which is a significant target for immunomodulatory therapies [3] - The company is conducting studies in various transplantation settings, including kidney, xenotransplantation, islet cell, liver transplantation, and ALS [3]

Core Viewpoint - GENFIT has received Orphan Drug Designation (ODD) from the U.S. FDA for its investigational drug NTZ (nitazoxanide) aimed at treating Acute-on-Chronic Liver Failure (ACLF), a severe condition with no approved therapies [1][6]. Group 1: Drug Development and Clinical Trials - G1090N is GENFIT's lead investigational program targeting ACLF, recognized by the FDA for its potential to address this life-threatening condition characterized by rapid deterioration and high mortality [2][6]. - Recent Phase 1 data showed a favorable safety and tolerability profile for G1090N in healthy volunteers, along with significant anti-inflammatory activity in ex vivo models, supporting the advancement to Phase 2 clinical development expected in the second half of 2026 [3][6]. Group 2: Regulatory and Market Implications - The ODD designation provides GENFIT with various development incentives, including FDA regulatory guidance, user fee reductions, and eligibility for seven-year U.S. market exclusivity upon FDA approval [3][6]. - The company aims to leverage this designation to enhance its development strategy and prospects in the ACLF segment, which is critical given the unmet medical needs in this area [5][6]. Group 3: Company Background and Focus - GENFIT is a biopharmaceutical company focused on rare and life-threatening liver diseases, with over two decades of research and development experience [4]. - The company also targets other serious conditions such as cholangiocarcinoma, urea cycle disorders, and organic acidemias, maintaining a diverse R&D portfolio [4].

Core Insights - The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GENFIT's investigational drug NTZ (nitazoxanide) for the treatment of Acute-on-Chronic Liver Failure (ACLF), a severe condition with no approved therapies [1][6] Company Overview - GENFIT is a biopharmaceutical company focused on rare and life-threatening liver diseases, with over two decades of research and development experience [4] - The company is headquartered in Lille, France, and has additional offices in Paris, Zurich, and Cambridge, MA [4] - GENFIT's R&D portfolio includes therapeutic assets targeting ACLF, acute decompensation (AD), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorders (UCD), and organic acidemias (OA) [4] Drug Development and Clinical Trials - G1090N is GENFIT's lead investigational program within the ACLF segment, recognized by the FDA for its potential to address this severe condition characterized by rapid deterioration and high short-term mortality [2][3] - Recent Phase 1 data showed a favorable safety and tolerability profile in healthy volunteers, along with strong anti-inflammatory activity in ex vivo models, supporting the advancement to Phase 2 clinical development targeted for the second half of 2026 [3][6] Regulatory Incentives - The ODD designation provides GENFIT with several development incentives, including FDA regulatory guidance, user fee reductions, and eligibility for seven-year U.S. market exclusivity upon FDA approval [3]

Core Viewpoint - Can-Fite BioPharma Ltd. announced positive results from a Phase IIa study of namodenoson for advanced pancreatic ductal adenocarcinoma (PDAC), highlighting its favorable safety profile and potential for further clinical evaluation [1][2][5]. Group 1: Study Results - The Phase IIa study met its primary endpoint of safety, showing that namodenoson was well tolerated in a heavily pretreated patient population with no new safety signals identified [2][3]. - The study enrolled 20 patients with advanced PDAC who had received one or more prior lines of therapy, representing a high-risk population [3]. - Secondary endpoints included overall survival (OS) and progression-free survival (PFS), with ongoing follow-up indicating that one-third of patients were alive at the time of data cut-off [4]. Group 2: Drug Profile and Designation - Namodenoson is a selective A3 adenosine receptor (A3AR) agonist that has shown anti-tumor activity in preclinical models and is also being evaluated for advanced liver cancer [5][6]. - The drug has received Orphan Drug Designation from the U.S. FDA for the treatment of pancreatic cancer, indicating its potential significance in addressing unmet medical needs [6]. Group 3: Company Overview - Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company focused on developing small molecule drugs for cancer and inflammatory diseases, with a pipeline addressing multi-billion dollar markets [7]. - The company’s lead drug candidate, Piclidenoson, has reported topline results in a Phase 3 trial for psoriasis and is advancing in clinical trials for other indications [7].

Core Insights - Grace Therapeutics, Inc. is a late-stage biopharma company focused on developing GTx-104, a novel injectable formulation of nimodipine for IV infusion aimed at treating aneurysmal subarachnoid hemorrhage (aSAH) patients [1][4] Company Overview - Grace Therapeutics specializes in drug candidates for rare and orphan diseases, utilizing innovative drug delivery technologies to enhance drug performance, including faster onset of action and reduced side effects [5] - The company has received Orphan Drug Designation from the FDA for its lead clinical asset, GTx-104, which provides seven years of marketing exclusivity post-launch in the U.S. under certain conditions [5] Product Details - GTx-104 is designed for IV infusion in aSAH patients, addressing significant unmet medical needs and potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients [4] - The product has been administered to over 200 patients and healthy volunteers, demonstrating good tolerance and significantly lower pharmacokinetic variability compared to oral nimodipine [4] Market Context - Aneurysmal subarachnoid hemorrhage (aSAH) accounts for approximately 5% of all strokes, with an estimated 42,500 hospital-treated patients in the U.S. [3]

Group 1: Netflix and Warner Bros. Discovery - Netflix has the capacity to increase its current offer of $27.75 per share for Warner Bros. Discovery's studio and streaming segments amid a bidding war with Paramount Skydance, which has proposed a $108.4 billion deal for the entire company [2][9] - Warner Bros. Discovery is set to hold a shareholder vote on Netflix's proposal on March 20, while giving Paramount seven days to submit a "best and final" offer [3] Group 2: U.S. Treasury and TIPS Auction - The recent auction of 30-year Treasury Inflation-Protected Securities (TIPS) yielded a high rate of 2.473%, down from 2.650% in the previous sale, indicating strong demand with a bid-to-cover ratio of 2.750 [4][5][9] Group 3: Federal Reserve Outlook - Federal Reserve Governor Stephen Miran has revised his interest rate projections for 2026, now suggesting a potential cut of 100 basis points instead of the previously anticipated 150 basis points, influenced by strong labor market data and rising goods inflation [6][7][9] Group 4: Corporate Finance Developments - Nippon Steel plans to raise $1.9 billion by selling off shareholdings to finance its $14.9 billion acquisition of U.S. Steel, which has recently cleared regulatory hurdles [8][9] Group 5: Biotech Developments - PureTech Health has received dual Orphan Drug Designation for its idiopathic pulmonary fibrosis candidate, LYT-100, from both the U.S. FDA and the European Commission, providing market exclusivity and development incentives [11][9] Group 6: Sovereign Debt Markets - Sri Lanka has initiated a tender offer for its $1 billion 5.875% bonds, offering to pay full principal plus 50.2% of accrued unpaid interest to bondholders, with results expected on March 16 [10]